Reuters ·  May 23 17:08
IDEAYA Biosciences Inc: About 67% Eye Preservation Rate With Darovasertib Monotherapy Neoadjuvant Uveal Melanoma Treatment
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment